|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:approvedBy
|
1978
|
|
gptkbp:ATCCode
|
N02AF01
|
|
gptkbp:availableOn
|
injectable solution
nasal spray
|
|
gptkbp:brand
|
gptkb:Stadol
|
|
gptkbp:CASNumber
|
42408-82-2
|
|
gptkbp:cause
|
withdrawal symptoms
|
|
gptkbp:chemicalFormula
|
C21H29NO2
|
|
gptkbp:contraindication
|
respiratory depression
hypersensitivity to butorphanol
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:eliminationHalfLife
|
5-6 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:has_stereochemistry
|
gptkb:levorphanol
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
butorphanol
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
|
|
gptkbp:isSynthetic
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
partial agonist at mu-opioid receptor
agonist at kappa-opioid receptor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
327.46 g/mol
|
|
gptkbp:notRecommendedFor
|
children under 18
patients with head injury
patients with severe asthma
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00619
60953
CHEMBL1201207
|
|
gptkbp:riskFactor
|
potential for abuse
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
nasal spray
|
|
gptkbp:sideEffect
|
nausea
dizziness
sweating
respiratory depression
sedation
|
|
gptkbp:UNII
|
YO3Y2D6FTW
|
|
gptkbp:usedFor
|
pain management
migraine treatment
labor pain
|
|
gptkbp:bfsParent
|
gptkb:dextrorphan
|
|
gptkbp:bfsLayer
|
7
|